Cargando…
A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to phase I clinical trials in advanced malignancies. N...
Autores principales: | Barghout, Samir H., Aman, Ahmed, Nouri, Kazem, Blatman, Zachary, Arevalo, Karen, Thomas, Geethu E., MacLean, Neil, Hurren, Rose, Ketela, Troy, Saini, Mehakpreet, Abohawya, Moustafa, Kiyota, Taira, Al-Awar, Rima, Schimmer, Aaron D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021101/ https://www.ncbi.nlm.nih.gov/pubmed/33476303 http://dx.doi.org/10.1172/jci.insight.141518 |
Ejemplares similares
-
Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
por: Majeed, Safa, et al.
Publicado: (2022) -
Inhibition of SREBP1 sensitizes cells to death ligands
por: Eberhard, Yanina, et al.
Publicado: (2011) -
Transduction of Primary AML Cells with Lentiviral Vector for In Vitro Study or In Vivo Engraftment
por: Schimmer, Aaron D., et al.
Publicado: (2020) -
GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma
por: Zhang, Xu, et al.
Publicado: (2022) -
Differential Inhibition of Human and Trypanosome Ubiquitin E1S by TAK-243 Offers Possibilities for Parasite Selective Inhibitors
por: Boer, D. Roeland, et al.
Publicado: (2019)